MENU
NRXP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

NRX Pharmaceuticals (NRXP) Earnings Date & Reports

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases... Show more

A.I. Advisor
published Earnings

NRXP is expected to report earnings to rise 38.67% to -24 cents per share on April 01

NRX Pharmaceuticals NRXP Stock Earnings Reports
Q4'26
Est.
$-0.25
Q3'26
Beat
by $0.11
Q2'26
Missed
by $0.33
Q4'25
Beat
by $0.53
Q3'25
Beat
by $0.25
The last earnings report on November 13 showed earnings per share of -18 cents, beating the estimate of -28 cents. With 503.59K shares outstanding, the current market capitalization sits at 103.04M.
A.I.Advisor
Nov 10, 2026

NRx Pharmaceuticals (NRXP) Earnings Preview: What to Watch Ahead of the Third-Quarter Report

Key Takeaways

  • NRx Pharmaceuticals is expected to report its third-quarter 2026 results around November 16, before the market opens.
  • Wall Street consensus calls for a loss of roughly $0.21 per share on approximately $1.22 million in revenue.
  • In the prior-year quarter, the company posted a loss of $0.27 per share on $242,000 in revenue.
  • Investor attention is likely to center on regulatory milestones for KETAFREE and NRX-100 rather than top-line figures alone.
  • For more on NRXP's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
  • Discover Trending AI Robots to see AI-driven trading ideas across the market.

Earnings Context and Why It Matters

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for conditions with limited or no existing treatment options. Because the company is not yet generating meaningful product revenue, its quarterly reports are watched less for sales than for progress toward regulatory approvals and commercial readiness. Management has guided toward a potential U.S. Food and Drug Administration (FDA) decision on its preservative-free ketamine candidate, KETAFREE, as well as an expanded application for NRX-100 targeting depression and suicidality. With the company still investing heavily in research and development, investors use the earnings update to gauge cash runway, spending trends, and the timeline to a potential break-even, all of which shape sentiment heading into the report.

Earnings Expectations

Consensus estimates for the third quarter of 2026 point to a net loss of about $0.21 per share on revenue near $1.22 million. That compares with a loss of $0.27 per share and $242,000 in revenue reported in the third quarter of 2025. In the most recent quarter, NRx Pharmaceuticals posted a loss of $0.44 per share, falling short of the roughly $0.11 loss analysts had projected, with revenue of $1.10 million also coming in below expectations. Given the company's early-stage profile, headline revenue and per-share figures can be volatile, so investors are likely to focus on management commentary regarding regulatory timelines, cash position, and any updates on at-the-market (ATM) equity offerings used to fund operations.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a useful companion for those tracking names like NRXP and their peers.

Market Reaction and Investor Sentiment

Sentiment heading into NRx Pharmaceuticals' third-quarter report is shaped more by pipeline catalysts than by quarterly financials. The stock has experienced notable volatility around prior earnings, reflecting both missed estimates and investor positioning tied to FDA-related news. Key risk factors include potential delays in regulatory decisions, competition in the ketamine treatment market, and the possibility of additional share issuance through the company's ATM facility, which could dilute existing shareholders. Because the company remains pre-revenue at scale, investors are likely to react primarily to updates on approval timelines, cash runway, and commercialization plans rather than to the raw earnings numbers themselves.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter print, the primary catalyst remains the regulatory pathway for KETAFREE and NRX-100. Management has indicated it anticipates an FDA decision on KETAFREE, with a target of achieving break-even by fiscal 2027 and projected revenue growth through 2026. Any shift in those timelines or in the scope of the indication sought for NRX-100 could meaningfully influence the outlook.

Investors should also monitor the company's cash position and operating expenses. NRx Pharmaceuticals has relied on ATM offerings to extend its runway, and further capital raises remain a possibility that could weigh on the share price. Research and development spending, along with general and administrative costs, have risen as the company advances toward a commercial launch.

Finally, broader industry dynamics matter. Competition in the ketamine and depression-treatment space continues to intensify, and the company's ability to differentiate KETAFREE as a preservative-free, U.S.-manufactured product will be central to its commercial story. Watching for partnership announcements, clinic expansion, and any update on the FDA's National Priority Voucher Program could provide additional signals about the path ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

is a blank check company, which engages in a stock exchange, asset acquisition, stock purchase, and reorganization

Industry Biotechnology

Industry
N/A
Address
1201 Orange Street
Phone
+1 484 254-6134
Employees
29
Web
https://nrxpharma.com